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Neuronal assemblies within the nervous system produce electrical activity that can be
recorded in terms of action potential patterns. Such patterns provide a sensitive endpoint
to detect effects of a variety of chemical and physical perturbations. They are a function
of synaptic changes and do not necessarily involve structural alterations. In vitro neu-
ronal networks (NNs) grown on micro-electrode arrays (MEAs) respond to neuroactive
substances as well as the in vivo brain. As such, they constitute a valuable tool for investi-
gating changes in the electrophysiological activity of the neurons in response to chemical
exposures. However, the reproducibility of NN responses to chemical exposure has not
been systematically documented. To this purpose six independent laboratories (in Europe
and in USA) evaluated the response to the same pharmacological compounds (Fluoxetine,
Muscimol, andVerapamil) in primary neuronal cultures. Common standardization principles
and acceptance criteria for the quality of the cultures have been established to compare
the obtained results. These studies involved more than 100 experiments before the ﬁnal
conclusions have been drawn that MEA technology has a potential for standard in vitro
neurotoxicity/neuropharmacology evaluation. The obtained results show good intra- and
inter-laboratory reproducibility of the responses. The consistent inhibitory effects of the
compounds were observed in all the laboratories with the 50% Inhibiting Concentrations
(IC50s) ranging from: (mean±SEM, in μM) 1.53± 0.17 to 5.4± 0.7 (n = 35) for Fluoxetine,
0.16± 0.03 to 0.38± 0.16μM (n = 35) for Muscimol, and 2.68± 0.32 to 5.23± 1.7 (n = 32)
for Verapamil. The outcome of this study indicates that the MEA approach is a robust tool
leading to reproducible results. The future direction will be to extend the set of testing
compounds and to propose the MEA approach as a standard screen for identiﬁcation and
prioritization of chemicals with neurotoxicity potential.
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INTRODUCTION
Neuronal activity is the primary functional output of the nervous
system and deviations from its physiological level often result in
adverse behavioral or physiological function.Neurotoxicity occurs
following exposure to a wide variety of xenobiotics that interfere
with the function of the nervous system and can be produced
by endogenous substances (mainly excitatory neurotransmitters)
under a variety of circumstances (Obrenovitch et al., 2000;Vincent
and Mulle, 2009). There are numerous mechanisms of action that
ultimately result in neurotoxic outcomes. However, compounds
are considered to be potentially neurotoxic when they affect a
neurospeciﬁc endpoint at concentrations that do not affect general
viability1 (Costa, 1998).
Detection and characterization of chemical-induced toxic
effects in the central and peripheral nervous system represent a
1These studies are generally carried out using cytotoxicity assays such as Neutral Red
(3-amino-7-di-methylamino-2-methylphenazine hydrochloride) uptake (NRU),
Alamar Blue or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT) reduction.
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major challenge for registration and assessment of chemicals (e.g.,
REACH directive) for two main reasons: (a) neurotoxic effects can
only be identiﬁed during in vivo studies for systemic toxicity evalu-
ation, (b) no in vitro methods for evaluating the neurotoxic hazard
of a chemical have yet been validated (Bal-Price et al., 2008).
Regulatory testing guidelines for the assessment of neurotoxic-
ity rely exclusively upon in vivo observations (see U.S. EPA Guide-
lines for Neurotoxicity Risk Assessment: FRL 6011-3 and OECD
TG481, TG419, TG424, and TG426). These include a number of
behavioral tests, speciﬁc neurophysiological measurements and
neuropathological examinations. The neurophysiological assess-
ments comprise methods based on the electrophysiological activ-
ity of neurons such as somatosensory, visual, and/or auditory
evoked potentials and electroencephalograms (EEGs). All of these
approaches exploit the fact that neuronal activity is the functional
output of the processes in the central and peripheral nervous sys-
tem. Thus, these measures can provide a sensitive endpoint to
detect early effects of chemicals before morphological changes
occur (Costa, 1998).
While animal models have been the gold standard in toxic-
ity testing for hazard identiﬁcation over the last ﬁve decades, this
approach is costly and time-consuming, and is not practical for
hazard identiﬁcation of thousands of chemicals such as under
the REACH directive or in the high production volume program.
Thus, alternative approaches to hazard identiﬁcation are needed
that have higher throughput capability and are predictive of in vivo
effects (Coecke et al., 2007; Lilienblum et al., 2008).
Whenneurons are grown in vitro, they retain the basic processes
underlying the in vivo physiological behavior. Their electrophysi-
ological activity can be measured by a variety of approaches. Thus,
in vitro assessment of neurophysiological function could be used
to screen chemicals for potential neuroactivity/neurotoxicity. Fur-
thermore while the seeding during the culture procedure leads to
a random distribution of neurons, the connectivity maps derived
from cultured neural assemblies are similar to other biological
networks and display non-trivial structure in clustering network
diameter, and assortative mixing (Bettencourt et al., 2007). One
of the most widely utilized approaches, patch-clamp recordings,
can provide exquisite mechanistic information about how a chem-
ical interacts with membrane-bound ion channels and membrane
reuptake transporters that ultimately control and modulate elec-
trical excitability of neurons. High-throughput platforms for con-
ducting patch-clamp electrophysiology are available, and have
been utilized by the pharmaceutical industry for drug develop-
ment. However, these platforms have some signiﬁcant drawbacks
from the standpoint of toxicity testing; they allow assessment of
only one channel type at a time, assess changes only in individual
cells rather than interconnected networks, and often require the
use of transfected (often non-neuronal) cell types. When screen-
ing chemicals for potential neuroactivity, speciﬁc targets will not
be known a priori, thus it would be impractical to screen multi-
ple ion channel types. Furthermore, assessment of how a chemical
affects communication between neurons in a networkwould iden-
tify actions that may be missed using measurements in individual,
transfected cells.
Novel methods like electrophysiological recordings from in
vitro neuronal networks (NNs) coupled to micro-electrode array
(MEA) chips provide a valuable alternative to conventional tech-
niques (Pancrazio et al., 2003; Köhling et al., 2005). The MEA is a
planar substrate with an embedded array of microelectrodes that
are capable of measuring extracellular electrophysiology (spikes
and bursts, i.e., packages of spikes) from electrically active tissues
(Thomas et al., 1972; Gross et al., 1977; Pine, 1980; Egert et al.,
1998).
Micro-electrode arrays are non-invasive, do not require exter-
nal manipulations and provide simpler approach and higher
content (up to hundreds of recording points) than conventional
electrophysiological techniques. Since the 1990s, MEAs have been
utilized for monitoring both acute and chronic effects of drugs
and toxins (Streit, 1993; Gross et al., 1997; Gramowski et al.,
2000; Shafer et al., 2008; Hogberg et al., 2011). In addition, MEA
approaches with increasingly higher throughput are becoming
available, which will facilitate rapid characterization of chemi-
cal actions on electrical activity in NNs. A recent review article
by Johnstone et al. (2010) has proposed the MEAs as a high
throughput, rapid screening method for toxicity testing.
Although MEAs have been used to study the actions of a variety
of pharmacological and toxicological chemicals, to date there have
been no multi laboratory studies that have evaluated the poten-
tial of this approach for formalized toxicity testing. Toward this
goal, the aim of the present project was to verify intra-laboratory
reproducibility and assess the interlaboratory variability of in vitro
electrophysiology from NNs coupled to MEA-based system as an
endpoint for an in vitro neurotoxicity test. Three reference chem-
icals: Fluoxetine2; Muscimol3; and Verapamil4 were studied in six
independent laboratories and the effects of these compounds on
eight classical descriptors of neuronal electrophysiology (the num-
ber of spikes and bursts, the mean network spike rate and mean
burst rate (MBR), the number of spikes in a burst, burst duration,
interburst interval, and percent of spikes occurring in a burst) have
been assessed. Among these parameters, the mean network spike
rate was uniformly among the most sensitive parameters to reﬂect
the neurotoxic effects of the applied test compounds. Thus the
within- and inter-laboratory reproducibility, accuracy and robust-
ness of the compounds’ effect on the mean ﬁring rate (MFR) has
been assessed. In addition, this study has also identiﬁed recom-
mendations on how the test system can be further improved in
terms of reliability, reproducibility, and throughput performance.
MATERIALS AND METHODS
CHEMICALS
Three chemicals were selected for the project:
1. R-(−)-Fluoxetine hydrochloride (FLU,SigmaAldrich – F1678),
CAS: 114247-09-5. FLU is a serotonin reuptake inhibitor. In
both vertebrates and invertebrates, serotonin functions as a
neuromodulator to either facilitate or inhibit synaptic activity
mediated by neurotransmitters (Fink and Göthert, 2007).
2http://www.chemspider.com/Chemical-Structure.3269.html
3http://http://www.chemspider.com/RecordView.aspx?rid=a969e9d6-172a-40ff-
8a47-fca9acc581db
4http://www.chemspider.com/Chemical-Structure.59223.html
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2. Muscimol hydrobromide (MUS, Sigma Aldrich – G019), CAS:
18174-72-6. MUS is a psychoactive alkaloid and it is a selec-
tive agonist of the GABAA receptor, thus enhancing the
inhibitory neurotransmission and suppressing spontaneous
activity. GABAergic agonists, like muscimol, are employed
mainly as antiepileptic drugs or in conjunction with antipsy-
chotics (Bartholini, 1985)
3. (±)-Verapamil hydrochloride (VER, Sigma Aldrich – V4629),
CAS: 152-11-4. VER is an L-type voltage-dependent calcium
channel antagonist. It blocks slow activating calcium channels
modulating the neuronal excitability and reducing electrical
activity (Rüschenschmidt et al., 2004).
Chemicals were purchased from the same stock from STU –
IHCP – JRC and distributed to the other partners. Mention
of trade names or commercial products does not constitute
endorsement or recommendation for use.
STUDY DESIGN
Six independent laboratories: HTS lab – Systems Toxicology Unit,
Institute for Health and Consumer Protection, Joint Research
Centre, Italy (IHCP); Department of Biological Sciences and Cen-
ter for Network Neuroscience (CNNS), University of North Texas,
Denton TX,USA; Neuroproof and Institute of Biological Sciences,
University of Rostock, Rostock (UR+NP), Germany; Integrated
Systems Toxicology Division., U. S. Environmental Protection
Agency (EPA), RTP,NC,USA; NeuroTech Lab – NBT, Italian Insti-
tute of Technology (IIT), Genoa, Italy; KBTLab – DIBE and ETT
joint lab (KBT), University of Genoa, Genoa, Italy participated in
the project. In each laboratory, each chemical was tested at least
three times with two different in vitro preparations from different
cultures.
During the study each participating laboratory adopted oper-
ating procedures and good laboratory practices for cell culture and
data processing. A priori deﬁned common acceptance criteria on
NN morphology and spontaneous electrophysiology were used to
select more than 100 independent experiments (about 700 h of
recordings) that were included in the analysis of reproducibility
between the laboratories (see Acceptance Criteria).
Each participating laboratory had its own well established
cortical neuronal model. Since this was an initial assessment of
interlaboratory reproducibility, attempts to standardize prepara-
tions were not made. Four different experimental models, namely
mouse cortex (E14–17), cryopreserved mouse cortex (E14–15), rat
cortex (E16–18), and new born (0–24 h) rat cortex, were used for
NN preparation (see Table 1).
Cell culture
Different cell densities have been used according to each labo-
ratory’s good practice protocols following previously published
methods. The number of seeded cells per chip was optimized by
each group to reach a ﬁnal density of 1500–2500 viable cells/mm2.
The viability of the cells was assessed with trypan blue test prior
to seeding and the appropriate volume of suspension was calcu-
lated to cover either the central part of the chip (with a 50-μl
droplet) or the whole surface depending on each laboratory pro-
tocol (see Table 1). Regardless of the cell source, once extracted
the cell suspension was added to the MEA device, medium was
added and the MEA chip was kept in a Petri dish (100mm) and
placed in a humidiﬁed incubator at 37˚C and 5% CO2 or 10%
CO2 (depending on the speciﬁc laboratory) in order to let the NN
reach maturation usually at 3–4weeks.
Once or twice a week the medium was changed until the
beginning of the experiment. Details on this aspect are given in
Table 1.
All procedures of the participating laboratories involving ani-
mals have been approved by the respective National Committees
on animal care and use for scientiﬁc research.
Chip handling and preparation
Standard 59–64 electrode MEA chips with 30μm diameter elec-
trodes, 150–200μm inter-electrode spacing (Multichannel Sys-
tems GmbH, Reutlingen, Germany; Center for Network Neuro-
science (CNNS) at the University of North Texas – MEA chip)
were employed. The MEA chips contained either an integrated
ground electrode, or an additional electrode was connected by the
user to the ground signal.
Prior to plating cells, the MEA chip was sterilized by heating
for 2 h in oven at 122˚C, or autoclaving. Subsequently, to pro-
mote adhesion and neurite outgrowth, the chip was coated with
Laminin (Sigma L2020) and Poly D-Lysine (PDL, Sigma P6407)
or Poly L-Lysine (PLL, Sigma 2636). The order and amount of
substrate deposition varied among laboratories (Table 1).
Recording system
The recording system consisted of (a) MEA ampliﬁer, (b) per-
sonal computer equipped with A/D acquisition board, (c) record-
ing software, (d) heating system and temperature controller, (e)
CO2 atmosphere-maintaining and evaporation-preventing sys-
tems. Speciﬁc details regarding the MEA-based recording systems,
electrophysiological activity sampling frequency, applied ﬁltering
and recording software are found in Table 2.
Figure 1 shows an example of a NN coupled to the MEA chip
and representative electrophysiological signal.
SIGNAL PROCESSING
Characterization of neuronal network electrophysiology
Raw electrophysiological signals consist of meaningful informa-
tion (spikes and bursts) superimposed on background noise.
Table 3 reports details about spike and burst detection methods.
In general the detection method is applied to each single MEA
channel: when the electrophysiological signal exceeds a thresh-
old an action potential (spike) is detected. The Plexon system has
the additional feature of allowing real-time spike identiﬁcation
based on wave shape (template matching) and discrimination
of up to four such shapes on each recording electrode (signal
channel). When a spike is detected the system stores the time
point of detection within the recording as a unit time stamp
(see Figure 2).
A burst is a dense sequence of spikes which can be recognized
by a burst detection method. Table 3 reports also details about
the methods utilized by each laboratory for both spike and burst
detection.
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Table 1 | Methods for neuronal culture and recordings among different laboratories.
IHCP CNNS EPA IIT KBT UR+NP
Parameter used for
IC50
Mean ﬁring rate Mean ﬁring rate Mean ﬁring rate Mean ﬁring rate Mean ﬁring rate Mean ﬁring rate
Model – cell culture (Cryo) mouse
cortex E14–15
Mouse frontal
cortex E15–E16
New born (0–24 h)
rat cortex
Rat cortex E18 Mouse cortex
E18
Mouse frontal cor-
tex E15–16
Dissociation No Dnase I+ papain Mechanical
(+ ﬁlter)
Trypsin Trypsin DNase I+ papain
Chip coating Laminin+PDL –
1:1 (just in the
center)
Laminin+PDL –
1:1
Laminin+PLL – 1:1 Laminin+PDL –
1:1 (just in the
center)
Laminin+PDL –
1:1 (just in the
center)
Laminin+PDL – 1:2
Number of
cells/chip
50000 300000 250000 50000 50000 300000
Culture medium Lonza medium DMEM+ 5%
serum (mus)
DMEM+ 5% (ﬂu)
Nbasal A+ 10%
FBS NBA/FBS+
Glutamate
Neurobasal B27 Neurobasal B27 Serum free
NeurobasalTM/
B27 (Invitrogen)
NbActive4 (GJ
Brewer)
Fraction and
frequency of the
medium change
(MC)
50% MC, once a
week for the ﬁrst
3weeks, then
50% MC two
times a week
there on
50% MC, two
times a week
100% MC, 1st after
24 h to
FBS+ glutamine
(1%). 2nd 3 days
later to FBS, then
once a week
thereon with FBS
50% MC, 1st
after 2/3 days,
then once a
week, two times
after 3/4weeks
50% MC, 1st
after 2/3 days,
then once a
week, two times
after 3/4weeks
30% three
times a week
(serum free),
50% two
times a week
(serum)
Antibiotics in cell
medium
YES NO YES NO NO NO
Presence of serum
while recording
NO YES YES NO NO NO
References Novellino and
Zaldívar (2010)
Xia et al. (2003) Meyer et al. (2008) Chiappalone et al.
(2006)
Chiappalone et al.
(2006)
Gramowski et al.
(2006)
Table 2 | Recording conditions across participating laboratories.
IHCP CNNS EPA IIT KBT UR+NP
Recording DIV 19–44 21–68 21–28 24–31 24–31 27–35
Recording
atmosphere
(CO2, pH,. . .)
Cap and water
vapor enriched
with 5%
CO2 + 20%
O2 +N2
Warmed cap and
water vapor+ 10%
CO2 + air
FEP
membrane+water
10μl per
administration
Cap and water vapor
enriched with 5%
CO2 + 20% O2 +N2
Cap and water vapor
enriched with 5%
CO2 + 20% O2 +N2
Warmed cap
and water
vapor+ 10%
CO2 + air
Recording
system
MEA system –
multi channel
systems
CNNS-MEA+Plexon MEA system – multi
channel systems
CNNS-MEA+Plexon MEA system – multi
channel systems
CNNS-
MEA+Plexon
Sampling
frequency
10 kHz 40 kHz 25 kHz 10 kHz 10 kHz 40 kHz
Other info Ampliﬁer gain
1000× Band pass
digital ﬁlter:
60–4000Hz
Ampliﬁer gain 10K
with bandpass set at
500–6000Hz
Ampliﬁer gain 1100×;
band pass digital
ﬁlter cutoff 200Hz
Ampliﬁer gain 1000× Ampliﬁer gain 1000×. Ampliﬁer gain
10K with
bandpass set at
500–6000Hz
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FIGURE 1 | An in vitro neuronal network (NN) at DIV 21
coupled to a microelectrode array (MEA) chip (left) and an example of
typical electrophysiological activity (right).This NN randomly self
re-assembled from cryopreserved cortical neurons of rat. The microelectrode
is 30 mm in diameter and the inter-electrode distance is 200μm. After
few weeks of in vitro culture it is possible to record both spikes and
bursts (the culture and the recording are from the ST Unit laboratory
at JRC).
FIGURE 2 | Extracellular raw electrophysiological signal, the extracted
spike and burst train. Burst duration and inter burst interval are illustrated
(electrophysiological trace recorded at the ST Unit laboratory of the JRC).
Spike trains were processed from the raw signals recorded
from each channel to extract descriptors of the spontaneous
electrophysiology at both spike and burst level, namely:
1. Number of spikes (summed over all the active channels in a
1-min bin),
2. Network MFR (spikes/s, summed over all the active channels),
3. Number of bursts (detected in the whole network in a 1-min
bin),
4. Network MBR (bursts/min),
5. Number of spikes in burst,
6. Mean Burst duration (ms),
7. Inter burst interval (IBI) (s),
8. Spikes in burst/total spikes (%SB/TS).
All the parameters were extracted at single channel level and inte-
grated over all the active channels in order to have descriptors at
network level.
Figure 3 displays an example of how these eight parameters are
distributed and affected by the application of muscimol.
Experimental procedure: from electrophysiology to
concentration–response curves
Experiments were carried from the third to the ninth week in vitro
(WIV).The recordingswereperformedondifferent days andusing
cultures from a minimum of two different isolations (see Table 2
for details).
In some laboratories a 50% change of the medium was con-
ducted prior to initiating the experiment (see Table 1 for details),
15–30min were allowed for the activity to stabilize before record-
ing. In all laboratories, reference activity recorded 30–60min
before the ﬁrst administration was used as the control condition.
Reagents were then introduced by the following pipetting proce-
dure to ensure propermixing: 100–300μl of mediumwas removed
from the medium bath covering the networks, mixed with a small
volume (2–20μl) of the reagent dilution and carefully returned to
the medium bath in order to minimize any osmotic or hydrody-
namic stress. Typically concentration–response relationships were
determined in a cumulative manner, in which the concentration
of drug present in the medium was increased in a stepwise manner
in log or half-log units.
All analyseswere conducted onbinneddatawith bin size of 60 s.
Data from experimental episodes were averaged for the last 20min
over the 30- to 40-min time window of recording for each concen-
tration (see Table 3 for details). Each time point of the experiment
was the average of the ﬁring rate over a 60-s time period. A sta-
ble level of spontaneous activity was required in order to start
the experiment and was considered as the reference. In general,
there is a transition period until equilibrium is achieved which
has been established by each laboratory with post hoc analysis in
previous experiments. The response during this transition time
window has not been considered for the concentration–response
analysis. The percent change in ﬁring rate at each concentration
was then determined relative to the reference spontaneous
activity period.
To determine the changes of network activity with time, mean
network spike rate, and burst rate of all active channels over the
course of the whole experiment were considered. For the purpose
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Table 3 | Signal processing methods.
Spike detection method Burst detection method Processing done on Reference for applied
methods
IHCP Threshold – MC_Rack (6–seven times
SD based on RMS).
Minimum number of spikes/burst= 5,
ISI max= 100ms, minimum bursting
rate/channel: 0.4 bursts/min.
20–25min (in stable activity). Chiappalone et al. (2005),
Novellino et al. (2009)
CNNS Plexon unit identiﬁcation and spike
detection.
Based on two thresholds adjusted
dynamically: ISI max= 50–150ms,
max time interval to end a burst:
100–300ms.
Minimum 30min of stable
activity.
Moreﬁeld et al. (2000),
Xia et al. (2003)
EPA MC_Rack threshold (−15μV, ∼2:1
noise of 5μV RMS).
Minimum nr. of spikes/burst= 4, ISI
max= 75ms.
10min in stable activity. Shafer et al. (2008)
IIT Precise timing spike detection (PTSD)
on raw data: eight times SD, peak
lifetime= 2ms, refractory
period= 3ms.
Minimum number of spikes/burst= 5,
ISI max= 100ms, minimum bursting
rate/channel: 0.4 bursts/min.
40min (after stable activity
is reached at each
administration).
Chiappalone et al. (2005),
Maccione et al. (2009)
KBT Precise timing spike detection (PTSD)
on raw data: eight times SD, peak
lifetime= 2ms, refractory
period= 3ms.
Minimum number of
spikes/channel= 5, ISI max= 100ms,
minimum bursting rate/channel: 0.4
bursts/min.
40min (after stable activity
is reached at each
administration).
Chiappalone et al. (2005),
Maccione et al. (2009)
UR+NP Plexon unit identiﬁcation and spike
detection.
Based on two thresholds adjusted
dynamically: ISI max= 50–150ms,
max time interval to end a bursts:
100–300ms.
30min stable activity (after
30min application
stabilization).
Moreﬁeld et al. (2000),
Gramowski et al. (2006)
of obtaining the IC50 values from the dose–response curve only the
changes inMFRwere considered. Plotswere alsoused todetermine
the concentration that stopped all activity.
Bursts were recognized and detected as trains of action poten-
tials based on a set of parameters deﬁned a priori and reported in
Table 3. The analysis on bursts was performed on 1-min bins as
well as for the MFR.
All the laboratories tested, in a subset of the experiments, the
viability of cells at the end of the recordings to assess that the
lack of activity was due to the neurotoxic but not to the cytotoxic
effect of each compound. This was done with a washout proce-
dure in two steps performed within 10min usually involving a
50% medium change (i.e., 500μl) followed by a 100% medium
change (1000μl). In all the cases full recovery of the activity was
observed (example shown in Figure 4).
In one laboratory (JRC) also a test based on the measurement
of lactate dehydrogenase (LDH) activity (Roche, Basel, Switzer-
land) was performed to have further evidence of the lack of
cytotoxicity of these three compounds. Samples of the medium
(150μl) were taken from the MEA chips at different times dur-
ing the experiment namely: (i) before starting the recordings;
(ii) at the end of the experiment during the ﬁrst step of the
wash out made with 50% change of the medium; and (iii) dur-
ing the second step of the wash out made with 100% change
of the medium. A negative control, 150μl of medium which
was not in contact with the cells was also submitted to LDH
measurement and a positive control with total LDH release by
neurons in the chip was determined after lysis by addition of 1%
Triton X-100 (Sigma, T8787). as previously done on neuronal cells
(Calderón et al., 1999).
Acceptance criteria
In a pre-study meeting the consortium deﬁned some simple rules
for considering the NN and its activity acceptable. The ﬁrst crite-
rionwas based on the networkmorphology and growth evaluation
done by a trained and experienced operator. On a regular basis
during the culture time and prior to MEA recording each chip was
inspected under an optical microscope to exclude the presence of
bacterial/fungal contamination. Furthermore before starting an
experiment each culture was evaluated for neuronal morphology
and network’s growth basing on the presence of a dense and uni-
form distribution of neuronal cells and the presence of neuronal
connections on the recording area as previously described (Hog-
berg et al., 2011 and see Figure 1). The second step in the quality
check was based on the electrophysiological activity analysis. The
network was considered acceptable for the study if the following
conditions were present:
• activity recorded from at least 15 electrodes
• synchronized burst patterns
• bursting frequency ≥6 burst/min (over the whole network)
• mean spiking frequency ≥6/s (for each channel)
• Number of spikes in bursts/all spikes ≥0.6
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FIGURE 3 | Graphical representation (mean±SEM) of the eight electrophysiological descriptors and their change upon application of FLU at different
concentrations compared to the reference value (N ). Data from JRC, N = 8 from three different cultures.
• signal-to-Noise (S/N) ratio: larger than2×RMSof the recorded
signal noise.
• SD of the IC50 obtained from single concentration–response
curves< 20% (see Statistical Analysis)
Statistical analysis
For each experiment, the changing spike rate as a function of
the concentration was ﬁtted with the Hill equation which has
long been proposed as a model to analyze non-linear drug
concentration–response relationships (Wagner, 1968):
y = ySTART + (yEND − ySTART)/(1 + 10[log(IC50)−log(x)]∗HC)
Where y is the observed value, ySTART is the highest observed
value, yEND is the lowest observed value (usually at the highest
concentration), and HC the Hill coefﬁcient which gives the largest
absolute value of the slope of the curve.
From this model the IC50 values were determined (using the
ﬁtting tool from Igor Pro 6.1, Wavemetrics Inc., USA) for each
compound and for each experiment.
The Hill equation was applied to single experiments where 20
points, each representing the MFR over a 1-min bin, were plotted
against the corresponding compound’s concentration. The IC50
was obtained with its own SD. If the SD was exceeding 20% of the
IC50 value the experiment was discarded from the dataset. When
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FIGURE 4 | An example of activity inhibition and recovery following washout (WO) withVER.The arrows indicate the time points of compound’s
application and the corresponding concentrations (data from JRC).
in each lab the set of experiments related to the same compound
was completed, the mean values (with SEM) of the MFR at each
concentrationwere plotted andﬁtted together and the IC50 ± SEM
for the compound was obtained.
For direct comparability all parameters were normalized in
each experiment with regard to the corresponding values of the
reference activity (native or after treatment, respectively).
The distribution of the calculated IC50 values for each com-
pound was tested by applying the one-way analysis of variance
(ANOVA). In this approach the calculated variableF,which reﬂects
both the variability within each dataset (intralaboratory variabil-
ity) and among the different datasets (interlaboratory variabil-
ity), is submitted to test. The result allows to assess whether the
expected values of a quantitative variable (i.e., the IC50) within
several pre-deﬁned groups differ from each other and to compare
the variability within each dataset and among different datasets.
Where signiﬁcant differences were detected a post hoc analysis with
pairwise multiple comparisons was applied to determine which of
the means differed. The one-way ANOVA and post hoc analysis
were performed with GraphPad Prism (GraphPad Software Inc.,
La Jolla, CA, USA) and the levels of signiﬁcance were p = 0.05 for
the F and p = 0.01 for the post hoc tests.
RESULTS
One hundred six cortical cultures were recorded in this interlabo-
ratory study. The age of the cultures ranged from DIV19 to DIV68.
The cultures exhibited spontaneous activity in their respective
media, consistent with previously reported effects (Xia et al., 2003;
Gramowski et al., 2004;Chiappalone et al., 2006; Shafer et al., 2008;
Pasquale et al., 2010).
Network spike rates ranged from (mean ± SEM) 3.2± 0.6
spikes/s (n = 25; cultures from new born rat) to 60.10 ± 7.04
spikes/s (n = 71; cultures from embryonic rat freshly dissociated
and embryonic mouse from cryopreserved vials). In spite of these
differences in the basal activity the results in terms of IC50 were
very homogeneous among the groups and for each compound (see
Table 4).
Addition of VER (1 pM–100μM), MUS (1 pM–3μM),
and FLU (1 pM–100μM) resulted in concentration-dependent
Table 4 | IC50 values determined in participating laboratories.
Laboratory Fluoxetine (μM) Muscimol (μM) Verapamil (μM)
IHCP 2.93± 0.11 0.20± 0.01 3.71± 1.23
CNNS 5.40± 0.70 0.16± 0.01 –
EPA 5.38± 0.41 0.42± 0.05 2.68± 0.32
IIT – 0.38± 0.01 5.23± 1.07
KBT 2.05± 0.10 – –
UR+NP 1.53± 0.17 0.21± 0.01 3.78± 0.23
Concentration–response curves for inhibition of mean spike rate by VER, MUS,
and FLU. MEAs containing cortex cells were exposed to MUS (1 pM–3μM), VER
(1 pM–100μM), and FLU (1 pM–100μM). Effects on spike rate were measured
by averaging the number of spikes/min over the last 10–30min of exposure to
each concentration, when a stable level of activity had been obtained. Each value
represents themean±SEMof 5–11 experiments for each participating laboratory.
decreases in the rates of spontaneous spiking and bursting activity,
and affected also the percentage of spikes in the bursts although
with less efﬁcacy (Figure 5). In some experiments, increases in the
spike and/or burst rate at low concentrations were observed prior
to decreases at higher concentrations (Figure 6) but this effect
was not consistently observed and was not statistically signiﬁcant
(paired t -test of the MFR and MBR compared with the values at
lower concentrations,p = 0.05). Therewere clear differences in the
inhibitory strength of the three compounds, but for each of them
every laboratory recorded the same order of magnitude of the IC50
value (see Table 4; Figure 7). The one-way ANOVA showed that
for both MUS and VER the differences among all the laboratories
were not signiﬁcant (p > 0.05) and that the intralaboratory and
interlaboratory variabilities were comparable (see Table 5). This
indicates that independently from the neuronal source (cryopre-
served/embryonic cortical neurons or newborn cortex) and from
the differences in the basal activity and the culture age the effects of
these two compounds were uniformly detected and reproducible
in all the laboratories (see Table 4).
The ANOVA on the FLU data has shown that there were signif-
icant differences among different laboratories. Thus we run a post
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FIGURE 5 | Normalized concentration–response curves for
MUS,VER, and FLU of the rates of spontaneous spiking (MFR),
bursting activity (MBR), and percent of spikes in the burst relative
to the total number of spikes (% SB/ST). As the ﬁring activity drops the
bursting activity decreases and so the %SB/TS. (data from the ST Unit
laboratory at JRC).
hoc (Newman–Keuls) test for multiple comparisons and we found
that both EPA and CNNS obtained a signiﬁcantly greater value of
the IC50 compared to the UR+NP laboratory (Figure 7; Table 5).
In spite of this the two of them were not signiﬁcantly different as
they were further tested with an unpaired t -test (p > 0.05). CNNS
and UR+NP were using the same cell model and same cell cul-
ture and signal analysis procedures. The source of this difference
is most probably related to the age of the cultures which, in the
case of FLU, may play a role (see Discussion). Both UR+NP and
the CNNS labs utilized cultures from embryonic mouse frontal
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FIGURE 6 | Example of activity inhibition in terms of spike rate (dashed black) and burst rate (dotted red) in response to FLU serial administrations
(data from the ST Unit laboratory at JRC).
cortex with CNNS performing experiments up to 9weeks in vitro,
while EPA performed its experiments on neurons obtained from
new born rat cortex when the developmental state of the neurons
is ahead compared to the embryonic stage. Yet there were no dif-
ferences compared to the other labs so this is an effect which can
be controlled by a better deﬁnition of the optimal culture age for
the recordings.
Among the three studied compounds MUS was the most
potent, while VER was the least potent (see Table 4).
The three compounds also inhibited theMBR,and burst related
parameters, in a concentration-dependent manner that was nearly
identical to effects on spike rate. Figure 3 reports an example
with Flu but a similar effect was observed also with the other
compounds.
Among the parameters used to quantify the effect of the three
compounds, the network MFR was identiﬁed as the best rep-
resenting parameter because it was sensitive to the compound’s
application, robust, simple to extract, and the effectiveness of the
detection was independent from the method applied by each labo-
ratory.Moreover the other parameters are derived froman analysis
(i.e., burst detection) of the ﬁring rate so we decided to concen-
trate on the IC50 derived from MFR as the endpoint to assess
the reliability and the reproducibility of the effects on neuronal
activity.
All participants observed that the decrease in network activ-
ity was not the result of cytotoxicity of MUS, VER or FLU to the
cultures since in a subset of experiments the washout of the com-
pound led to full recovery of the initial spike rate (see Figure 4 as
an example). Even after spiking and bursting activity was inhib-
ited by >90%, events were still recorded. Furthermore in one
lab (JRC), an LDH release test was performed to have further
evidence of the lack of cytotoxicity of these three compounds
and the results are summarized in Table 6 (see Experimental
Procedure: From Electrophysiology to Concentration–Response
Curves).
DISCUSSION
The present study examined the robustness and reproducibility
of in vitro NNs coupled to MEA-based systems as a ﬁrst step
in demonstrating the utility of this approach for neurotoxicity
screening. The results of this study demonstrate consistency across
different laboratories in determining the magnitude of the effects
for three pharmaceutical agents. Indeed for both MUS and VER,
the variability of the IC50 values determined across all the par-
ticipating laboratories were comparable to the variability detected
within each laboratory independently from the culture source and
age. The same occurs for FLUwhen analyzing the data from all lab-
oratories except for CNNS (older cultures age) and EPA (postnatal
cortex neurons).
FLU deserves particular consideration because the age of the
culture may inﬂuence the effect of the compound on the elec-
trical activity. FLU acts on the serotonergic system by inhibiting
the serotonin (5-HT) reuptake thus enhancing its the effect. Sev-
eral published data provide evidence that the serotonergic system
undergoes a dramatic change within the late embryonic phase and
the ﬁrst weeks of postnatal life and that the effects of 5-HT on
neuronal excitability (and thus activity) may vary a lot within this
timewindow(Hedner andLundborg,1980;Aitken andTörk,1988;
Béïqueet al., 2004). Thus experiments performed on cell cultures
which span widely through this time period may be affected by the
variability of the response related to the rapid changes occurring
in the serotonergic pathway.
Still the reproducibility observed in the two subgroups (all lab-
oratories except EPA and CNNS and EPA+CNNS) demonstrates
the robustness of MEA approaches. Data derived from MEAs were
already shown to be reproducible within an individual laboratory
(e.g., Gramowski et al., 2004, 2006; Parviz and Gross, 2007). The
present results extend this reproducibility across multiple labora-
tories and recording platforms. This reproducibility was evident
despite the fact that different experimental models (see Table 1),
as well as culture practices, and commercially available recording
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FIGURE 7 | Graphical representation of the IC50 for each compound and
for all the participating laboratories (mean±SEM). For FLU signiﬁcant
differences (*) were detected from two labs (EPA and CNNS). Further
analysis revealed a possible inﬂuence of the culture age on the effects
measured.
systems (i.e.,MultiChannel Systems GmbH, and Plexon Inc.) were
used across the different participating laboratories.
In vitro networks of neurons are spontaneously active and
express patterns of electrical activity as part of their normal
function (Gross et al., 1997; van Pelt et al., 2005; Wagenaar et al.,
2006).While there have been limited studies of effects of neurotox-
icants usingMEAs (see Johnstone et al., 2010), to date these studies
have focused on understanding actions of individual chemicals.
These studies have established that effects of compounds at the cel-
lular level recorded with MEAs produce histiotypic responses that
correlate with their characteristic signs and symptoms of intoxi-
cation (e.g., Xia and Gross, 2003; Meyer et al., 2008; Shafer et al.,
2008). Furthermore, the alterations of electrical activity induced
by a compound’s application (functional neurotoxicity), is often
not to the result of cell death (cytotoxicity). This is consistent
with the acute neurotoxicity of many xenobiotics (e.g., ethanol,
pyrethroids, and tetrodotoxin) that cause the organism death
prior to the onset of signiﬁcant cytotoxicity/pathology in the ner-
vous system. While not systematically examined in the present
experiments, the measurements of LDH release indicate that the
compounds assessed in the present study also exerted changes
in network activity in the absence of cytotoxicity. This ability of
MEAs to detect changes in network function that either precede or
occur in the absence of signiﬁcant cytotoxicity make them a useful
and sensitive approach for screening chemicals for neurotoxicity
potential.
Compared to patch-clamp and other single electrode record-
ing techniques, MEA approaches measure responses of a whole
network, integrating global information on the interaction of all
receptors, synapses and neuronal types which are present in the
network. Furthermore, recently developed new technology of the
MEA devices allows to increase the throughput. Already avail-
able 12-wells chips with up to 64 electrodes per well allow to
simultaneously record neuronal activity in 12 different experi-
mental conditions and very soon platforms which accommodate
up to 96-chips in a plate with up to 798 recording channels will
be available making the MEA a potential candidate for stan-
dard screening of neurotoxic compounds. In addition, because
of the integrated nature of function in MEA recordings, they are
closer to the whole animal situation than data from single cell
or single ion channel studies, and allow for feedback and com-
pensation to take place within the network. While the present
studies utilized primary cultures from dissociated tissue, it is
possible to measure activity in slices from several CNS regions,
thereby preserving the three dimensional structure of the CNS, if
desired.
As a ﬁrst result, the present study demonstrates that MUS,
FLU, and VER effects on network activity are characterized by
an overall decrease in spiking and bursting activity in a potent
and concentration-dependent manner. These results are con-
sistent with patch-clamp and MEA recordings from previous
studies (Xia et al., 2003) where FLU decreased the number of
spikes and bursts, decreased the percentage of spikes occurring
in a burst, and increased both the ISI and IBI or indirectly
inhibited electrical activity by enhancing GABAergic transmission
(Ye et al., 2008).
The effects that we observed with FLU on dissociated neuronal
cultures are in agreement with published data on primary cul-
tures (frontal and auditory cortices) showing that 10–20μM FLU,
similar to the range that we used, induced complete inhibition of
electrical activity (Xia et al., 2003).
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Table 5 | Analysis of variance with one-way ANOVA on the IC50s from each compound in the different labs.
Compound F value with DF Estimate interlab variability Estimate intralab variability Sign. difference p
MUS F (4,27)= 3.86 0.078 0.020 No 0.015
VER F (3,24)= 1.32 5.89 4.46 No 0.29
FLU F (4,40)= 5.88 28.6 4.86 Yes 0.134
FLU* F (2,20)= 2.22 9.48 4.27 No 0.0008
The variable F with the dataset degrees of freedom (DF) was obtained as the ratio between the estimate inter- and intra-lab variability and is submitted to the
statistical test. Both the estimate intra- and interlab variabilities are obtained with the sum of squares of the differences with the corresponding means. p is the critical
probability value of the corresponding F. When a signiﬁcant difference in the dataset was detected a post hoc multiple comparisons test (Newman–Keuls) with level
of conﬁdence p= 0.01 was run to perform pairwise multiple comparisons and detect more in detail the ones which were different. In the last row of the table FLU*
indicates reﬁned statistical analysis when the IC50 values for FLU from both EPA and CNNS were excluded from the dataset.
Table 6 | CellViability with LDH release following exposure to test compounds.
Compound LDH in neurobasal at the start of the recording 50%WO 100%WO LDH in the Medium (neg. control) Triton X-100
FLU 21 13 5 1 172
VER 22 20 13 4 147
MUS 21 18 13 2 264
Viability of cells on MEAs was assessed by measuring LDH release in the medium before and at the end of an experiment during the 2-steps washout (WO) procedure.
The measurement was performed with the Cobas Integra 400 System (F. Hoffmann-La Roche AG, Basel, Switzerland) and values are expressed as IU/l.
The present experiments demonstrate that in vitro NNs retain
electrical responses which resemble those from their original brain
tissue. In fact our results gave evidence that the three compounds
exerted inhibition of spontaneous activity at a similar magnitude
compared to what previously observed in vivo and on primary
cultures (Wada et al., 1995; Heinke et al., 2004; Darbin and
Wichmann, 2008).
These effects are consistent across:
– four different cortex sources, namely mouse cortex (E14–15),
cryopreserved mouse cortex (E14–15), rat cortex (E16–18), and
new born (0–24 h) rat cortex;
– six culture cell-chip practice protocols;
– two different recording platforms (Multi Channel Systems and
Plexon);
– three different spike detection methods (two commercial and
provided with recording system and one method developed “in
house”).
Basing on the differences detected with FLU one recommendation
is to narrow the time window for recording in relation to the cul-
ture age. In fact when considering only the experiments on embry-
onic neuronal cultures at younger age the results obtained were
consistent and the intralaboratory and interlaboratory variabilities
were also comparable.
During drug development and pharmacological evaluation,
an efﬁcient and reliable experimental platform is needed for
drug screening prior to in vivo whole animal testing. The
multi-unit recording of cultured NNs represents a valuable
advance with many advantages, including better control of com-
pound concentrations, moderate throughput rates (it is possible
to record from different systems in parallel), and easy data
interpretation.
The present study has demonstrated the reproducibility of the
MEA approach for three pharmaceutical compounds. The repro-
ducibility and the sensitivity of this method make it an eligible
candidate tool for systematic analysis and priority ranking of
chemical compounds for hazard assessment.
However, to gain acceptance as a potential approach for screen-
ing and prioritizing chemicals for potential neurotoxicity, addi-
tional studies need to be conducted that examine broader classes
of neuroactive/neurotoxic chemicals, and approaches for com-
pound classiﬁcation (Gross et al., 1997; Chiappalone et al., 2003;
Gramowski et al., 2004) must be extended to also include well
known classes of neurotoxicants. Future studies are planned to
examine effects of neurotoxic and non-neurotoxic compounds
and describe further relative potency and structure–activity rela-
tionships. The results of such studies will provide further proof
of principle that MEA recordings will be useful for neurotoxicity
testing.
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